{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-065663","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.724645+00:00","generated_at":"2026-05-18T09:31:35.916547+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity","bullets":["Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.","Combined CA19-9 and INNOCS platform achieved >95% sensitivity and >99% specificity in a 1,086-subject cohort.","Liminatus will lead regulatory filings with FDA and KMFDS upon commercialization phase.","Global pancreatic cancer diagnostics market projected at $3B by 2026; blood-based segment >$700M.","Consortium to leverage AI, biomarker platform, and Liminatus's regulatory/commercial infrastructure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-065663","json":"https://secwatch.observer/filing/0001104659-25-065663.json","markdown":"https://secwatch.observer/filing/0001104659-25-065663.md","text":"https://secwatch.observer/filing/0001104659-25-065663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/0001104659-25-065663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/tm2519876d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:31:35.916547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}